Mechanisms by which troglitazone improves insulin resistance in NIDDM
$0M01FY2002RRNIH
Temple University, Philadelphia PA
Investigators
Linked publications & trials
Paper 30137555Paper 20194829Paper 17949927Paper 17120297Paper 17071216Paper 16961692Paper 16868831Paper 16768601Paper 16720337Paper 16457777Paper 16416175Paper 16272292Paper 15932362Paper 15916622Paper 15800559Paper 15767618Paper 15235061Paper 15107299Paper 15104362Paper 15086868Paper 15056089Paper 14720034Paper 14717972Paper 14624413Paper 12962693Paper 12866995Paper 12832307Paper 12757160Paper 12660140Paper 12546685Paper 12141833Paper 12135014Paper 12034027Paper 12028371Paper 11768254Paper 11743243Paper 11323422Paper 11270790Paper 11270782Paper 11181007Paper 11051357Paper 11007121Paper 10898747Paper 10644487
Abstract
The objectives of this study are to test in patients with NIDDM the hypotheses that treatment with Troglitazone 1)decreases leptin mRNA and protein in muscle and that the decrease in muscle leptin synthesis correlates with the improvement in insulin resistance; 2) lowers plasma FFA and triglyceride levels by inhibiting rates of lipolysis, and/or by increasing rates of FFA oxidation or FFA reesterification and 3) improves insulin stimulated glucose uptake (i.e., lowers insulin resistance) by lowering of plasma FFA levels.
View original record on NIH RePORTER →